Hightech Receptor Ab

Sumitomo Chemical Company, Limited

Pharmacia Ab

Sumitomo Pharmaceuticals Company Limited

Pharmacia Lkb Biotechnology Ab

Actinova Limited

Hansa Medical Ab

Lars Bjorck

Rikard Holmdahl

Fumitaka Kishimoto

Hideyuki Gomi

Shizuo Hattori

Tatsunobu Hozumi

Chiaki Tagawa

Goran Kronvall

Gunnar Lindahl

Bertil Christensson

Adam Linder

Kutty Selva Nandakumar

William H Kastern

Ulf Sjobring

Erling Myhre

Mats Erntell

Arne Olsen

Heiko Herwald

Per Akesson

The invention relates to sequences of protein L which bind to light chains of immunoglobulins. The invention also relates to hybrid proteins thereof which are able to bind to both light and heavy chains of immunoglobulin G, in particular protein LG. The invention also relates to DNA-sequences which code for the proteins, vectors which include such DNA-sequences, host cells which have been transformed with the vectors, methods for producing the proteins, reagent appliances for separation and identification of immunoglobulins, compositions and pharmaceutical compositions and pharmaceutical compositions which contain the proteins.

Protein L and hybrid proteins thereof

A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. AP1 and expressed in host cells, E. coli to produce the Protein H.

Gene encoding a novel protein H capable of binding to IgG

A gene coding for Protein H, which is capable of binding specifically to human IgG of all subclasses, was isolated from Streptococcus sp. APl and expressed in host cells, E. coli to produce the Protein H.

Protein H capable of binding to IgG

A hybrid DNA molecule is disclosed by this invention capable of cellular expression comprising the DNA sequence for protein G. Said DNA sequence has substantially the same IgC binding properties as naturally occurring protein G. The molecule may be comprised of DNA sequences coding for fragments of protein G. Moreover, said DNA sequence may code for both fragments of protein G and protein G. The DNA sequence can be isolated from streptococcal DNA.

Protein G and/or fragments thereof

A process is disclosed for recovering a cell wall protein, particularly a Fc-receptor, from streptococcal bacteria. In the process, streptococcal bacteria are treated with at least one proteolytic enzyme to solubilize the cell wall protein. A process is also disclosed for recovering Fc-receptor type III (protein G) having selective IgG-binding capability (i.e., no albumin-binding capability) from streptococcal bacteria by pretreating these bacteria with enzymes prior to said enzymatic solubilization.

Purified protein G from streptococcal bacteria

This invention relates to a new protein L and subfragments thereof with binding activity for all classes of immunoglobulins from different species, a process for preparing the same, a reagent kit, a pharmaceutical composition and strain 312 of P. magnus. The process for preparing the protein and subfragments thereof is characterized in that the microorganism P. magnus 312 is treated with proteolytic enzymes or mutanolysin.

Protein L and subfragments thereof, with immunoglobulin binding

Growing community of inventors

Sodra Sandby, Sweden

Lars Bjorck